Anuh Pharma Limited
NSE: ANUHPHR · Pharmaceuticals · sector
₹77.06NSE close 2026-10-26
Key numbers
Market cap₹772 cr
Price₹77.06
52w high / low₹100 / ₹67
P/E17.5xSector median 27.9x
P/B2.2xSector median 2.9x
Book value₹35.1
Dividend yield1.93%Sector median 0.48%
ROE13.0%Sector median 11.7%
ROCE17.2%Sector median 12.3%
OPM8.3%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA11.1xSector median 18.6x
Interest cover228.6x
Current ratio2.22x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹53 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 228.6x in the last 12 months.
- Other income was 16% of net profit in the last 12 months.
- Dividend paid in 1 of the last 2 financial years.
- Price ₹77.06 on 2026-10-26: -22.6% from the 52-week high, +15.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹230.50 · low ₹71.40
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 160 | 198 | 186 | 186 | 197 | 202 | 194 |
| EBITDA | 15 | 19 | 10 | 12 | 17 | 20 | 16 |
| OPM % | 9.3% | 9.4% | 5.5% | 6.4% | 8.5% | 9.8% | 8.4% |
| Other income | 1 | 1 | 3 | 1 | 4 | -1 | 3 |
| Net profit | 10 | 12 | 8 | 8 | 13 | 12 | 11 |
| EPS (₹) | 1.03 | 1.25 | 0.83 | 0.76 | 1.34 | 1.17 | 1.14 |
| Revenue YoY | +23.6% | +2.0% | +3.9% | ||||
| Profit YoY | +30.1% | -6.3% | +37.6% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY25 | FY26 | TTM |
|---|---|---|---|
| Revenue | 662 | 772 | 779 |
| EBITDA | 61 | 62 | 65 |
| Net profit | 47 | 41 | 44 |
| EPS (₹) | 4.72 | 4.10 | 4.41 |
| Revenue growth | +16.7% | – | |
| Profit growth | -13.3% | – | |
| Dividend / share (₹) | – | 1.50 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | -2.8% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 326 | 352 |
| Borrowings | 10 | 0 |
| Cash & equivalents | 74 | 53 |
| Total assets | 507 | 557 |
| Fixed assets | 50 | 48 |
| Capital work in progress | 0 | 0 |
| Investments | 52 | 40 |
| Receivables | 216 | 239 |
| Inventory | 74 | 148 |
| Payables | 157 | 188 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 37 | -3 |
| Cash from investing | -20 | 18 |
| Cash from financing | -5 | -26 |
| Capex | 20 | 8 |
| Free cash flow | 17 | -11 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 14.5% | 11.7% |
| ROCE % | 18.3% | 15.5% |
| Debtor days | 119 | 113 |
| Inventory days | 54 | 90 |
| Payable days | 115 | 114 |
| Cash conversion cycle (days) | 58 | 89 |
| Working capital days | 109 | 117 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 71.80% |
| FIIs | 0.11% |
| DIIs | 0.00% |
| of which Mutual funds | 0.00% |
| Public (non-institutions) | 28.09% |
| Quarter | Mar 2025 | Jun 2025 | Jul 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 69.92% | 69.92% | 69.92% | 71.82% | 71.82% | 71.80% | 71.80% | 71.80% |
| Promoter group | % |
|---|---|
| Bharti Bipin Shah | 19.43% |
| Prafulla Lalit Shah | 14.47% |
| Bipin Nemchand Shah | 8.48% |
| Bipin Nemchand Shah | 6.21% |
| Bharat Nemchand Shah | 3.73% |
| Gaurav Satish Shah | 3.19% |
| Mrudula Jayantilal Shah | 2.33% |
| Vivek Bipin Shah | 2.33% |
| Ritesh Bipin Shah | 2.31% |
| Dina Satish Shah | 2.22% |
| Samir Jayantilal Shah | 1.72% |
| Kinjal Siddharth Jhaveri | 0.81% |
| Jasmine Samir Shah | 0.66% |
| Neeta Ketan Shah | 0.52% |
| Harshit Bharat Shah | 0.50% |
| Public holders above 1% | % |
|---|---|
| Michael Dsouza | 1.20% |
28,447 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ANUHPHR | ₹772 cr | 17.5x | 2.2x | 13.0% | 17.2% | 8.3% | – | 1.93% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-08-05 | Dividend | Dividend - Rs 1.50 Per Share |
| 2025-08-14 | Dividend | Dividend - Rs 1.50 Per Share |
| 2025-07-15 | Bonus | Bonus 1:1 |
Documents
- Annual report FY26
- Annual report FY25
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ANUHPHR |
| BSE code | 506260 |
| ISIN | INE489G01022 |
| Face value | ₹5.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.